Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 20.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,969 shares of the company’s stock after purchasing an additional 3,458 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Travere Therapeutics were worth $279,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. Aigen Investment Management LP acquired a new position in shares of Travere Therapeutics in the 3rd quarter worth approximately $170,000. Assenagon Asset Management S.A. raised its stake in Travere Therapeutics by 912.5% during the second quarter. Assenagon Asset Management S.A. now owns 2,214,099 shares of the company’s stock worth $18,200,000 after acquiring an additional 1,995,419 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of Travere Therapeutics during the third quarter valued at $673,000. Acadian Asset Management LLC grew its holdings in shares of Travere Therapeutics by 202.6% in the 2nd quarter. Acadian Asset Management LLC now owns 144,901 shares of the company’s stock worth $1,190,000 after purchasing an additional 97,020 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of Travere Therapeutics by 33.9% during the 2nd quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock worth $24,244,000 after purchasing an additional 747,406 shares in the last quarter.
Travere Therapeutics Trading Down 1.0 %
Shares of NASDAQ TVTX opened at $19.22 on Monday. Travere Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $20.33. The firm has a market capitalization of $1.50 billion, a P/E ratio of -4.22 and a beta of 0.69. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The company’s 50 day simple moving average is $17.66 and its 200 day simple moving average is $12.32.
Wall Street Analyst Weigh In
A number of research firms have commented on TVTX. Wedbush boosted their price target on shares of Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a research report on Wednesday, October 9th. Scotiabank increased their price target on Travere Therapeutics from $23.00 to $27.00 and gave the stock a “sector outperform” rating in a research report on Friday, November 1st. Barclays lifted their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Bank of America raised their target price on Travere Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Finally, Guggenheim upped their price target on shares of Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.62.
Check Out Our Latest Analysis on Travere Therapeutics
Insiders Place Their Bets
In related news, Director Jeffrey A. Meckler sold 40,000 shares of the stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $14.06, for a total value of $562,400.00. Following the sale, the director now directly owns 81,000 shares in the company, valued at $1,138,860. This trade represents a 33.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Sandra Calvin sold 12,090 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $18.30, for a total transaction of $221,247.00. Following the transaction, the chief accounting officer now owns 54,927 shares of the company’s stock, valued at approximately $1,005,164.10. This represents a 18.04 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 92,090 shares of company stock worth $1,372,847. Insiders own 3.75% of the company’s stock.
Travere Therapeutics Profile
Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Read More
- Five stocks we like better than Travere Therapeutics
- What is a Stock Market Index and How Do You Use Them?
- Guidewire Software Provides Long-Awaited Buying Opportunity
- What Are Dividends? Buy the Best Dividend Stocks
- What’s Behind These 3 Recent Analyst Stock Upgrades?
- How to Invest in Small Cap StocksÂ
- Fast-Growing Companies That Are Still Undervalued
Want to see what other hedge funds are holding TVTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report).
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.